Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET
Authors: De Meyer Steffi , Schaeverbeke Jolien M , Luckett Emma S , Reinartz Mariska , Blujdea Elena R , Cleynen Isabelle , Dupont Patrick , Van Laere Koen , Vanbrabant Jeroen , Stoops Erik , Vanmechelen Eugeen , di Molfetta Guglielmo , Zetterberg Henrik , Ashton Nicholas J , Teunissen Charlotte E , Poesen Koen , Vandenberghe Rik 
Published: May 2024

Abstract
The dynamic phase of preclinical Alzheimer’s disease, as characterized by accumulating cortical amyloid-β, is a window of opportunity for amyloid-β–lowering therapies to have greater efficacy. Biomarkers that accurately predict amyloid-β accumulation may be of critical importance for participant inclusion in secondary prevention trials and thus enhance development of early Alzheimer’s disease therapies. We compared the abilities of baseline plasma pTau181, pTau217 and amyloid-β PET load to predict future amyloid-β accumulation in asymptomatic elderly. In this longitudinal cohort study, baseline plasma pTau181 and pTau217 were quantified using single molecule array assays in cognitively unimpaired elderly selected from the community-recruited F-PACK cohort based on the availability of baseline plasma samples and longitudinal amyloid-β PET data (median time interval = 5 years, range 2–10 years). The predictive abilities of pTau181, pTau217 and PET-based amyloid-β measures for PET-based amyloid-β accumulation were investigated using receiver operating characteristic analyses, correlations and stepwise regression analyses. We included 75 F-PACK subjects (mean age = 70 years, 48% female), of which 16 were classified as amyloid-β accumulators [median (interquartile range) Centiloid rate of change = 3.42 (1.60) Centiloids/year). Plasma pTau181 [area under the curve (95% confidence interval) = 0.72 (0.59–0.86)] distinguished amyloid-β accumulators from non-accumulators with similar accuracy as pTau217 [area under the curve (95% confidence interval) = 0.75 (0.62–0.88) and amyloid-β PET [area under the curve (95% confidence interval) = 0.72 (0.56–0.87)]. Plasma pTau181 and pTau217 strongly correlated with each other (r = 0.93, Pfalse discovery rate &lt; 0.001) and, together with amyloid-β PET, similarly correlated with amyloid-β rate of change (rpTau181 = 0.33, rpTau217 = 0.36, ramyloid-β PET = 0.35, all Pfalse discovery rate ≤ 0.01). Addition of plasma pTau181, plasma pTau217 or amyloid-β PET to a linear demographic model including age, sex and APOE-ε4 carriership similarly improved the prediction of amyloid-β accumulation (ΔAkaike information criterion ≤ 4.1). In a multimodal biomarker model including all three biomarkers, each biomarker lost their individual predictive ability. These findings indicate that plasma pTau181, plasma pTau217 and amyloid-β PET convey overlapping information and therefore predict the dynamic phase of asymptomatic amyloid-β accumulation with comparable performances. In clinical trial recruitment, confirmatory PET scans following blood-based prescreening might thus not provide additional value for detecting participants in these early disease stages who are destined to accumulate cortical amyloid-β. Given the moderate performances, future studies should investigate whether integrating plasma pTau species with other factors can improve performance and thus enhance clinical and research utility.